Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
Chemotherapy based on the sequential use of anthracyclines and taxanes has long represented the most efficacious approach in the management of early-stage, triple-negative breast cancer, whose aggressive behavior is widely renowned. This standard chemotherapy backbone was subsequently enriched by th...
Main Authors: | Daniele Marinelli, Marco Mazzotta, Laura Pizzuti, Eriseld Krasniqi, Teresa Gamucci, Clara Natoli, Antonino Grassadonia, Nicola Tinari, Silverio Tomao, Isabella Sperduti, Giuseppe Sanguineti, Andrea Botticelli, Agnese Fabbri, Claudio Botti, Gennaro Ciliberto, Maddalena Barba, Patrizia Vici |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/9/2497 |
Similar Items
-
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
by: Giacomo Barchiesi, et al.
Published: (2020-05-01) -
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
by: Antonino Grassadonia, et al.
Published: (2021-07-01) -
Cancer patients and coronavirus disease 2019: evidence in context
by: Maddalena Barba, et al.
Published: (2020-08-01) -
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
by: Marco Mazzotta, et al.
Published: (2019-02-01) -
Neoadjuvant Treatment in Pancreatic Cancer
by: Atsushi Oba, et al.
Published: (2020-02-01)